
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/571168/publications.pdf Version: 2024-02-01



Μλάν Ελάξι

#	Article	IF	CITATIONS
1	Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet, The, 2007, 369, 1947-1954.	6.3	751
2	Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood, 2015, 126, 1033-1040.	0.6	565
3	Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood, 2011, 118, 282-288.	0.6	549
4	Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncology, The, 2010, 11, 653-660.	5.1	532
5	Current Use of and Trends in Hematopoietic Cell Transplantation in the United States. Biology of Blood and Marrow Transplantation, 2020, 26, e177-e182.	2.0	378
6	Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. Blood, 2017, 129, 1548-1556.	0.6	340
7	Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell–Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide. Journal of Clinical Oncology, 2017, 35, 3002-3009.	0.8	255
8	Higher Mortality After Allogeneic Peripheral-Blood Transplantation Compared With Bone Marrow in Children and Adolescents: The Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. Journal of Clinical Oncology, 2004, 22, 4872-4880.	0.8	246
9	The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy. Blood, 2016, 127, 260-267.	0.6	245
10	Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR. Blood, 2019, 134, 924-934.	0.6	199
11	Effect of donor–recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis. Lancet Oncology, The, 2011, 12, 1214-1221.	5.1	192
12	Peripheral Blood Grafts from Unrelated Donors Are Associated with Increased Acute and Chronic Graft-versus-Host Disease without Improved Survival. Biology of Blood and Marrow Transplantation, 2007, 13, 1461-1468.	2.0	174
13	A trial of unrelated donor marrow transplantation for children with severe sickle cell disease. Blood, 2016, 128, 2561-2567.	0.6	174
14	Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. Blood, 2006, 107, 4961-4967.	0.6	154
15	Outcomes after Hematopoietic Stem Cell Transplantation for Children with I-Cell Disease. Biology of Blood and Marrow Transplantation, 2014, 20, 1847-1851.	2.0	150
16	Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia. Blood, 2011, 118, 2618-2621.	0.6	131
17	Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study. Lancet Haematology,the, 2019, 6, e585-e596.	2.2	128
18	Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial. Blood, 2021, 137, 420-428.	0.6	119

#	Article	IF	CITATIONS
19	Comparable Long-Term Survival After Unrelated and HLA-Matched Sibling Donor Hematopoietic Stem Cell Transplantations for Acute Leukemia in Children Younger Than 18 Months. Journal of Clinical Oncology, 2006, 24, 145-151.	0.8	93
20	PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL. Blood Advances, 2019, 3, 360-369.	2.5	92
21	Hematopoietic stem cell transplantation for infantile osteopetrosis. Blood, 2015, 126, 270-276.	0.6	89
22	HLA Haploidentical versus Matched Unrelated Donor Transplants with Post-Transplant Cyclophosphamide based prophylaxis. Blood, 2021, 138, 273-282.	0.6	88
23	Alternative Donor Transplantation for Older Patients with Acute Myeloid Leukemia in First Complete Remission: A Center for International Blood and Marrow Transplant Research-Eurocord Analysis. Biology of Blood and Marrow Transplantation, 2014, 20, 816-822.	2.0	80
24	Outcome of hematopoietic cell transplantation for DNA double-strand break repair disorders. Journal of Allergy and Clinical Immunology, 2018, 141, 322-328.e10.	1.5	79
25	Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies. Blood, 2018, 132, 1438-1451.	0.6	78
26	Relationship between Mixed Donor–Recipient Chimerism and Disease Recurrence after Hematopoietic Cell Transplantation for Sickle Cell Disease. Biology of Blood and Marrow Transplantation, 2017, 23, 2178-2183.	2.0	74
27	Allele-level HLA matching for umbilical cord blood transplantation for non-malignant diseases in children: a retrospective analysis. Lancet Haematology,the, 2017, 4, e325-e333.	2.2	72
28	HLA-Matched Sibling Hematopoietic Stem Cell Transplantation for Fanconi Anemia: Comparison of Irradiation and Nonirradiation Containing Conditioning Regimens. Biology of Blood and Marrow Transplantation, 2008, 14, 1141-1147.	2.0	69
29	Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide. Blood Advances, 2018, 2, 299-307.	2.5	69
30	Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity. Blood Advances, 2018, 2, 2095-2103.	2.5	66
31	Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1–2 dose de-escalation study. Lancet Haematology,the, 2015, 2, e367-e375.	2.2	64
32	Haematopoietic stem cell transplantation for refractory Langerhans cell histiocytosis: outcome by intensity of conditioning. British Journal of Haematology, 2015, 169, 711-718.	1.2	56
33	Long-term Survival, Organ Function, and Malignancy after Hematopoietic Stem Cell Transplantation for Fanconi Anemia. Biology of Blood and Marrow Transplantation, 2016, 22, 1257-1263.	2.0	56
34	Donor and recipient sex in allogeneic stem cell transplantation: what really matters. Haematologica, 2016, 101, 1260-1266.	1.7	54
35	Bone Marrow or Peripheral Blood for Reduced-Intensity Conditioning Unrelated Donor Transplantation. Journal of Clinical Oncology, 2015, 33, 364-369.	0.8	51
36	Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Children and Adolescents with Fanconi Anemia. Biology of Blood and Marrow Transplantation, 2017, 23, 310-317.	2.0	50

#	Article	lF	CITATIONS
37	Engraftment kinetics and graft failure after single umbilical cord blood transplantation using a myeloablative conditioning regimen. Haematologica, 2014, 99, 1509-1515.	1.7	48
38	Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission. Cancer, 2017, 123, 2025-2034.	2.0	48
39	Related and unrelated donor transplantation for β-thalassemia major: results of an international survey. Blood Advances, 2019, 3, 2562-2570.	2.5	48
40	Mismatched Related and Unrelated Donors for Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2014, 20, 1485-1492.	2.0	43
41	Low CD34 Dose Is Associated with Poor Survival after Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2014, 20, 1418-1425.	2.0	40
42	Effect of antithymocyte globulin source on outcomes of bone marrow transplantation for severe aplastic anemia. Haematologica, 2017, 102, 1291-1298.	1.7	38
43	Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft- <i>versus</i> -host disease: low incidence of lower gastrointestinal tract disease. Haematologica, 2018, 103, 717-727.	1.7	38
44	Myeloablative vs reduced intensity T-cell–replete haploidentical transplantation for hematologic malignancy. Blood Advances, 2019, 3, 2836-2844.	2.5	38
45	Hematopoietic Cell Transplantation with Cryopreserved Grafts for Severe Aplastic Anemia. Biology of Blood and Marrow Transplantation, 2020, 26, e161-e166.	2.0	38
46	Long-Term Survival and Late Deaths after Hematopoietic Cell Transplantation for Primary Immunodeficiency Diseases and Inborn Errors of Metabolism. Biology of Blood and Marrow Transplantation, 2012, 18, 1438-1445.	2.0	37
47	Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. Blood Advances, 2019, 3, 3123-3131.	2.5	37
48	Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch?. Blood Advances, 2018, 2, 1180-1186.	2.5	35
49	Long-Term Survival after Transplantation of Unrelated Donor Peripheral Blood or Bone Marrow Hematopoietic Cells for Hematologic Malignancy. Biology of Blood and Marrow Transplantation, 2015, 21, 55-59.	2.0	34
50	Nonmyeloablative Alternative Donor Transplantation for Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR. Journal of Clinical Oncology, 2020, 38, 1518-1526.	0.8	34
51	Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission. Biology of Blood and Marrow Transplantation, 2014, 20, 202-208.	2.0	33
52	Cohort-Controlled Comparison of Umbilical Cord Blood Transplantation Using Carlecortemcel-L, a Single Progenitor–Enriched Cord Blood, to Double Cord Blood Unit Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 1463-1470.	2.0	31
53	Killer Cell Immunoglobulin-Like Receptor–Ligand Matching and Outcomes after Unrelated Cord Blood Transplantation in Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2016, 22, 1284-1289.	2.0	28
54	Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. Leukemia, 2021, 35, 2076-2085.	3.3	28

#	Article	IF	CITATIONS
55	Outcomes after Second Hematopoietic Cell Transplantation in Children and Young Adults with Relapsed Acute Leukemia. Biology of Blood and Marrow Transplantation, 2019, 25, 301-306.	2.0	27
56	Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors. Blood Advances, 2021, 5, 975-983.	2.5	27
57	Risk score to predict event-free survival after hematopoietic cell transplant for sickle cell disease. Blood, 2020, 136, 623-626.	0.6	26
58	Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes. Transplantation and Cellular Therapy, 2022, 28, 409.e1-409.e10.	0.6	26
59	Graft-Versus-Host Disease and Survival after Cord Blood Transplantation for Acute Leukemia: A Comparison of Japanese versus White Populations. Biology of Blood and Marrow Transplantation, 2014, 20, 662-667.	2.0	25
60	Transplantation Outcomes for Children with Hypodiploid Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2015, 21, 1273-1277.	2.0	24
61	Umbilical Cord Blood Transplantation in Children with Acute Leukemia: Impact of Conditioning on Transplantation Outcomes. Biology of Blood and Marrow Transplantation, 2017, 23, 1714-1721.	2.0	24
62	Hematopoietic Stem Cell Transplantation for Shwachman-Diamond Syndrome. Biology of Blood and Marrow Transplantation, 2020, 26, 1446-1451.	2.0	24
63	Alternative donor transplantation for acute myeloid leukemia in patients aged ≥50 years: young HLA-matched unrelated or haploidentical donor?. Haematologica, 2020, 105, 407-413.	1.7	23
64	InÂVivo T Cell Depletion with Myeloablative Regimens on Outcomes after Cord Blood Transplantation for Acute Lymphoblastic Leukemia in Children. Biology of Blood and Marrow Transplantation, 2015, 21, 2173-2179.	2.0	21
65	Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50Years or Older with Severe Aplastic Anemia. Biology of Blood and Marrow Transplantation, 2019, 25, 488-495.	2.0	21
66	Functional and Radiologic Assessment of the Brain after Reduced-Intensity Unrelated Donor Transplantation for Severe Sickle Cell Disease: Blood and Marrow Transplant Clinical Trials Network Study 0601. Biology of Blood and Marrow Transplantation, 2019, 25, e174-e178.	2.0	21
67	A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation. Blood, 2021, 137, 983-993.	0.6	20
68	Alternative Donor Transplantation for Aplastic Anemia. Hematology American Society of Hematology Education Program, 2010, 2010, 43-46.	0.9	19
69	Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy: efficacy of hematopoietic stem cell transplantation. Haematologica, 2014, 99, 1868-1875.	1.7	19
70	Bone Marrow versus Peripheral Blood from Unrelated Donors for Children and Adolescents with Acute Leukemia. Biology of Blood and Marrow Transplantation, 2018, 24, 2487-2492.	2.0	19
71	Comparison of haploidentical and umbilical cord blood transplantation after myeloablative conditioning. Blood Advances, 2021, 5, 4064-4072.	2.5	17
72	Effect of Cord Blood Processing on Transplantation Outcomes after Single Myeloablative Umbilical Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 688-695.	2.0	16

#	Article	IF	CITATIONS
73	Comparison of hematopoietic cell transplant conditioning regimens for hemophagocytic lymphohistiocytosis disorders. Journal of Allergy and Clinical Immunology, 2022, 149, 1097-1104.e2.	1.5	16
74	The effect of inter-unit HLA matching in double umbilical cord blood transplantation for acute leukemia. Haematologica, 2017, 102, 941-947.	1.7	15
75	Practice pattern changes and improvements in hematopoietic cell transplantation for primary immunodeficiencies. Journal of Allergy and Clinical Immunology, 2018, 142, 2004-2007.	1.5	14
76	Transplant Outcomes in Acute Leukemia (I). Seminars in Hematology, 2010, 47, 46-50.	1.8	13
77	Personalized Prognostic Risk Score for Long-Term Survival for Children with Acute Leukemia after Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 1523-1530.	2.0	13
78	Comparison of total body irradiation <i>versus</i> non-total body irradiation containing regimens for de novo acute myeloid leukemia in children. Haematologica, 2021, 106, 1839-1845.	1.7	13
79	Hematopoietic Stem Cell Transplantation Positively Affects the Natural History of Cancer in Nijmegen Breakage Syndrome. Clinical Cancer Research, 2021, 27, 575-584.	3.2	13
80	Umbilical Cord Blood or HLA-Haploidentical Transplantation: Real-World Outcomes versus Randomized Trial Outcomes. Transplantation and Cellular Therapy, 2022, 28, 109.e1-109.e8.	0.6	12
81	Principles and analysis of hematopoietic stem cell transplantation outcomes: the physician's perspective. Lifetime Data Analysis, 2008, 14, 379-388.	0.4	11
82	No Survival Advantage After Double Umbilical Cord Blood (UCB) Compared to Single UCB Transplant in Children with Hematological Malignancy: Results of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0501) Randomized Trial. Blood, 2012, 120, 359-359.	0.6	11
83	Optimal Donor for African Americans with Hematologic Malignancy: HLA-Haploidentical Relative or Umbilical Cord Blood Transplant. Biology of Blood and Marrow Transplantation, 2020, 26, 1930-1936.	2.0	10
84	Second Allogeneic Hematopoietic Cell Transplantation for Patients with Fanconi Anemia and Bone Marrow Failure. Biology of Blood and Marrow Transplantation, 2015, 21, 1790-1795.	2.0	9
85	Changing Trends of Unrelated Umbilical Cord Blood Transplantation for Hematologic Diseases in Patients Older than Fifty Years: A Eurocord-Center for International Blood and Marrow Transplant Research Survey. Biology of Blood and Marrow Transplantation, 2016, 22, 1717-1720.	2.0	9
86	Survival after T-Cell Replete Haplo-Identical Related Donor Transplant Using Post-Transplant Cyclophosphamide Compared with Matched Unrelated Donor Transplant for Acute Myeloid Leukemia. Blood, 2014, 124, 679-679.	0.6	8
87	Outcomes in Hematopoietic Stem Cell Transplantation for Congenital Amegakaryocytic Thrombocytopenia. Transplantation and Cellular Therapy, 2021, 28, 101.e1-101.e1.	0.6	7
88	Long-term Survival after Hematopoietic Cell Transplant for Sickle Cell Disease Compared to the United States Population. Transplantation and Cellular Therapy, 2022, 28, 325.e1-325.e7.	0.6	7
89	Unrelated donor transplantation: Peripheral blood or bone marrow – Does it matter?. Best Practice and Research in Clinical Haematology, 2014, 27, 278-282.	0.7	6
90	Superiority of Pediatric Chemotherapy over Allogeneic Hematopoietic Cell Transplantation for Philadelphia Chromosome Negative Adult ALL in First Complete Remission: A Combined Analysis of Dana-Farber ALL Consortium and CIBMTR Cohorts. Blood, 2014, 124, 319-319.	0.6	6

#	Article	IF	CITATIONS
91	Effect of Race on Outcomes After Allogeneic Hematopoietic Cell Transplantation for Severe Aplastic Anemia. Blood, 2011, 118, 1020-1020.	0.6	6
92	Allogeneic transplantation for aplastic anemia. Hematology, 2012, 17, s15-s17.	0.7	5
93	A Multicenter Phase II Trial of Unrelated Donor Reduced Intensity Bone Marrow Transplantation for Children with Severe Sickle Cell Disease (SCURT): Results of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0601) Study. Blood, 2015, 126, 619-619.	0.6	5
94	Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy. Transplantation and Cellular Therapy, 2021, 27, 993.e1-993.e8.	0.6	4
95	Use of Peripheral Blood Grafts Is Associated with Increased Acute and Chronic Graft-Versus-Host Disease without Improved Survival after Unrelated Donor Transplantation Blood, 2005, 106, 443-443.	0.6	4
96	Effect of Stem Cell Source on Transplant Outcomes in Adults with Acute Leukemia: A Comparison of Unrelated Bone Marrow (BM), Peripheral Blood (PB) and Cord Blood (CB). Blood, 2008, 112, 151-151.	0.6	4
97	Hematopoietic Stem Cell Transplantation from HLA Identical Sibling Forsickle Cell Disease an International Survey on Behalf of Eurocord-Monacord, EBMT Paediatric Disease Working Party and CIBMTR. Blood, 2015, 126, 541-541.	0.6	4
98	Impact of Center Experience with Donor Type on Outcomes: A Secondary Analysis, Blood and Marrow Transplant Clinical Trials Network 1101Open for Accrual June 2012Open for Accrual June 2012. Transplantation and Cellular Therapy, 2022, 28, 406.e1-406.e6.	0.6	4
99	Relapsed acute lymphoblastic leukemia: Is it crucial to achieve molecular remission prior to transplant?. Best Practice and Research in Clinical Haematology, 2017, 30, 317-319.	0.7	3
100	The Effect of Granulocyte Colony-Stimulating Factor Use on Hospital Length of Stay after Allogeneic Hematopoietic Cell Transplantation: A Retrospective Multicenter Cohort Study. Biology of Blood and Marrow Transplantation, 2020, 26, 2359-2364.	2.0	3
101	Comparison of Peripheral Blood Stem Cells (PBSC) to Bone Marrow (BM) for T-Replete HLA-Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide. Blood, 2016, 128, 683-683.	0.6	3
102	A resurgence of cord blood transplantation?. Lancet Haematology,the, 2020, 7, e89-e90.	2.2	2
103	T-Replete Haploidentical Cell Transplantation Using Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome: Effect of Transplant Conditioning Regimen Intensity on Outcomes. Blood, 2018, 132, 1015-1015.	0.6	2
104	Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Versus Matched Unrelated Donor. Blood, 2019, 134, 3323-3323.	0.6	2
105	Unrelated Donor Transplantation for Fanconi Anemia: Analysis of Prognostic Factors Impacting Engraftment and Survival Blood, 2004, 104, 824-824.	0.6	2
106	Donor-Recipient Matching at the HLA-C Locus and Early Outcomes after Unrelated Umbilical Cord Blood Transplant (UCBT). Blood, 2008, 112, 153-153.	0.6	2
107	Analysis of Risk Factors Influencing Outcomes After Unrelated Cord Blood Transplantation In Children with Juvenile Myelomonocytic Leukemia. An Eurocord, EBMT, EWOG-MDS, CIBMTR Study. Blood, 2010, 116, 533-533.	0.6	2
108	Bone Marrow or Peripheral Blood. Biology of Blood and Marrow Transplantation, 2010, 16, 868-869.	2.0	1

#	Article	IF	CITATIONS
109	Hematopoietic cell transplantation for acute leukemia: selecting donors. Haematologica, 2015, 100, 414-415.	1.7	1
110	Surviving childhood cancer: a sobering story. Blood, 2018, 131, 2603-2604.	0.6	1
111	Related and Unrelated Donor Transplantation for Î ² Thalassemia Major: Results of an International Survey. Blood, 2018, 132, 308-308.	0.6	1
112	Hematopoietic Recovery and Overall Survival after HLA-Matched Sibling Transplants for Older Patients with Severe Aplastic Anemia (SAA) Blood, 2008, 112, 2169-2169.	0.6	1
113	Impact of In Vivo T-Cell Depletion on Outcome of Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplantation (HCT) for Hematologic Malignanciesimpact of In Vivo T-Cell Depletion on Outcome of Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies, Blood, 2010, 116, 2305-2305,	0.6	1
114	Transplant Conditioning Regimens and Outcomes After Allogeneic Hematopoietic Cell Transplantation (HCT) In Children and Adolescents with Acute Lymphoblastic Leukemia (ALL). Blood, 2010, 116, 3506-3506.	0.6	1
115	Reduced Intensity Conditioning (RIC) Transplantation In Acute Leukemia: The Effect of Source of Unrelated Donor Stem Cells on Outcomes. Blood, 2010, 116, 908-908.	0.6	1
116	Graft-Versus-Host Disease (GVHD) Induced Graft-Versus-Leukemia (GVL) Effect: More Impact on Later Relapse and Disease-Free Survival Following Reduced Intensity Conditioning. Blood, 2011, 118, 1014-1014.	0.6	1
117	Umbilical Cord Blood (UCB) Transplantation in Children with Acute Leukemia: Impact of Conditioning Regimen on Transplant Outcomes. Blood, 2016, 128, 1231-1231.	0.6	1
118	Since everyone has a donor, why are some eligible patients still not transplanted?. Best Practice and Research in Clinical Haematology, 2021, 34, 101321.	0.7	1
119	Risk Factors for Graft Failure and Mortality after HLA-Matched Sibling Donor Transplant for Severe Aplastic Anemia in Brazil Blood, 2007, 110, 622-622.	0.6	1
120	Rapid Transport and Infusion of Hematopoietic Stem Cells Can Improve Outcome after Unrelated Donor Transplant Blood, 2007, 110, 3063-3063.	0.6	1
121	The Presence of HLA DR15 Antigen in Patients with Severe Aplastic Anemia Does Not Impact Engraftment and Survival After HLA-Identical Sibling Transplantation Blood, 2009, 114, 2280-2280.	0.6	1
122	The Effect of Transplant Center Characteristics On Survival After Pediatric Hematopoietic Cell Transplantation. Blood, 2012, 120, 762-762.	0.6	1
123	Is There Any Effect of Killer Cell Immunoglobulin-like Receptor (KIR) on Outcomes after Single Unrelated Cord Blood Transplantation?. Blood, 2014, 124, 48-48.	0.6	1
124	Selecting between HLA-Matched Siblings and HLA- Haploidentical Related Donors for Acute Leukemia in the Era of Post-Transplant Cyclophosphamide: The Center for International Blood and Marrow Transplant Registry and the Acute Leukemia Working Party of the European Society for Blood and Marrow Marrow Transplant. Blood, 2017, 130, 851-851.	0.6	1
125	HCT for SCID: one size does not fit all. Blood, 2017, 129, 2826-2827.	0.6	0
126	Is a matched sibling the ideal donor for hematopoietic cell transplant?. Haematologica, 2018, 103, 1251-1252.	1.7	0

#	Article	IF	CITATIONS
127	In-vivo T-cell depletion: burden of morbidity versus survival. Lancet Haematology,the, 2019, 6, e63-e64.	2.2	0
128	Engraftment of Double Cord Blood Transplantation after Nonmyeloablative Conditioning with Escalated Total Body Irradiation Dosing to Facilitate Engraftment in Immunocompetent Patients. Transplantation and Cellular Therapy, 2021, 27, 879.e1-879.e3.	0.6	0
129	Family Cord Blood Banking: Experience and Views of Pediatric Hematopoietic Stem Cell Transplant Physicians Blood, 2004, 104, 3323-3323.	0.6	Ο
130	Outcomes after HLA-Matched Sibling Transplants or Chemotherapy in Children with Acute Lymphoblastic Leukemia in Second Remission: A Collaborative Study of the Children's Oncology Group (COG) and the Center for International Blood and Marrow Transplant Research (CIBMTR) Blood, 2005, 106, 174-174.	0.6	0
131	Risk Factors and Outcome after Second HLA-Matched Sibling Donor Transplantation for Graft Failure after a First HLA-Matched Sibling Transplant in Severe Aplastic Anemia Blood, 2007, 110, 1110-1110.	0.6	0
132	Risks and Benefits of Unrelated Donor Peripheral Blood Progenitor Cells (PBPC) in Children and Adolescents with Acute Leukemia Blood, 2008, 112, 977-977.	0.6	0
133	Encoraging Results after Alternative Donor Transplantation for Myelodysplastic Syndrome Blood, 2008, 112, 1964-1964.	0.6	0
134	Donor Characteristics Affecting Graft Failure and Survival after Unrelated Donor Transplantation with Reduced Intensity Conditioning Regimens (RIC) for Hematologic Malignancies Blood, 2008, 112, 1968-1968.	0.6	0
135	Chronic Graft-Versus-Host Disease and Its Association with Treatment-Related Mortality, Relapse, Leukemia-Free and Overall Survival After Umbilical Cord Blood Transplantation (UCBT) In Children and Adolescents with Acute Leukemia. Blood, 2010, 116, 213-213.	0.6	0
136	Effect of Stem Cell Source From Unrelated Donors on Transplant Outcomes In Severe Aplastic Anemia (SAA): a Comparison of Unrelated Bone Marrow (BM) and Peripheral Blood Progenitor Cells (PBPC). Blood, 2010, 116, 531-531.	0.6	0
137	Fludarabine-Based Conditioning for Allogeneic Marrow Transplantation From Unrelated Donors in Severe Aplastic Anemia (SAA): Serious and Unexpected Adverse Events in Pre-Defined Cyclophosphamide (CY) Dose Levels. Blood, 2011, 118, 3009-3009.	0.6	0
138	Outcome of Transplantation for Acute Leukemia in Down Syndrome. Blood, 2012, 120, 1991-1991.	0.6	0
139	Hematopoietic Cell Transplant Versus Chemotherapy As Consolidation Treatment for Pediatric AML with Poor-Risk Cytogenetics. Blood, 2012, 120, 127-127.	0.6	0
140	Alternative Donor Hematopoietic Transplantation For Patients Older Than 50 Years With AML In First Complete Remission: Unrelated Donor and Umbilical Cord Blood Transplantation Outcomes. Blood, 2013, 122, 302-302.	0.6	0
141	Comparable 3-Year Disease-Free Survival Regardless of Anti-Thymocyte Globulin Inclusion in Pediatric Myeloablative Cord Blood Transplantation for Acute Lymphoblastic Leukemia. Blood, 2014, 124, 1259-1259.	0.6	0
142	A Phase II Trial to Compare Allogeneic Transplant Vs. Standard of Care for Severe Sickle Cell Disease: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 1503. Blood, 2019, 134, 4592-4592.	0.6	0
143	Long-Term Survival and Late Death after Hematopoietic Cell Transplant for Patients with Sickle Cell Disease Surviving for at Least Two-Years after Transplantation. Blood, 2021, 138, 410-410.	0.6	0
144	Impact of Center Experience with Donor Type and Treatment Platform on Outcomes: A Secondary Analysis BMT CTN 1101. Blood, 2021, 138, 3956-3956.	0.6	0

#	Article	IF	CITATIONS
145	Comparison of Outcomes after Haploidentical Relative and HLA Matched Unrelated Donor Transplantation with Post-Transplant Cyclophosphamide Containing Gvhd Prophylaxis Regimens. Blood, 2020, 136, 21-22.	0.6	0
146	Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplant for Hyperinflammatory Inborn Errors of Immunity. Blood, 2020, 136, 36-37.	0.6	0
147	Cost effectiveness of reduced intensity conditioning and transplantation of unrelated umbilical cord blood versus HLA haploidentical related bone marrow for adults with hematologic malignancies Journal of Clinical Oncology, 2022, 40, 6591-6591.	0.8	О